After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Investors pummeled Eli Lilly and Co.’s stock Wednesday on the news that its experimental drug for Alzheimer’s disease failed to help patients, but a chorus of pharmaceutical analysts say they weren't shocked by the setback.
Research developed at Purdue University and licensed by a biomedical startup could give patients with late-stage prostate cancer an alternative to hormone therapies that can develop resistance after prolonged use.
Eli Lilly and Co. is pledging $90 million over five years to improve access to treatment for diabetes, cancer and tuberculosis in developing countries—the latest push in its philanthropic strategy of building health care systems around the world and increasing the market for its prescription drugs.